Delivery Order SPE2DB25D2204-SPE2DB25FTGWF
- Not listed
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $8,141.67, represents a non-competitive set-aside procurement and is scheduled for ultimate completion by August 1, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $3,770.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of XELJANZ XR 11 mg tablets in unit-of-use 30-count packaging. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed price delivery order valued at $25,624.50, with performance completion scheduled for September 15, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was not designated as a set-aside contract and represents a competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 tablets per unit. This competitively awarded, non-set-aside contract carries a firm fixed price ceiling value of $2,662.07 and is scheduled for completion by July 23, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $4,091.04 on November 25, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, completed competitively through open procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 26, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of XELJANZ XR 11 mg tablets in a quantity of 30 units, with a ceiling value of $1,599.24. This firm fixed-price delivery order is not associated with a set-aside designation and represents a competitive award to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of XELJANZ XR 11 mg tablets in a quantity of 30 units, valued at $8,055.93. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by September 16, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order is issued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $25,562.44 delivery order on September 12, 2025, for XELJANZ XR 11 mg tablets (30-count units) with a completion date of September 15, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of approximately $46,067 and has a firm fixed price structure, with an ultimate completion date of August 7, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGWFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order has a ceiling value of $25,621.47 and an ultimate completion date of August 14, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency and military healthcare operations. As a non-set-aside award, this delivery order reflects the contractor's capability to compete successfully for federal pharmaceutical supply requirements. The company's extensive federal portfolio demonstrates consistent delivery of brand-name and generic medications across multiple therapeutic domains, including specialty treatments and vaccines, supporting the military healthcare supply chain through flexible and comprehensive contract vehicles designed to meet global demand.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.6k | 8/13/25 |